SCHEMBL2320148

SCHEMBL2320148

Cc1[c]ccc(Cl)c1-c1ccccc1C

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLA2G7 Q13093 1/20 0.36
NPC1 O15118 4/20 0.33
RAB9A P51151 4/20 0.33
CYP1A2 P05177 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
CASP3 P42574 2/20 0.33
SENP8 Q96LD8 2/20 0.33
SENP7 Q9BQF6 2/20 0.33
SENP6 Q9GZR1 2/20 0.33
CYP1A1 P04798 1/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
TSHR P16473 2/20 0.33
HPGD P15428 2/20 0.33
HSD17B10 Q99714 1/20 0.33
ACHE P22303 1/20 0.32
MAP2 P11137 1/20 0.32
PBRM1 Q86U86 1/20 0.32
HEXA P06865 1/20 0.32
HEXB P07686 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1982913 0.85 PLA2G7 (0.36) PLA2G7NPC1RAB9ACYP1A2SMN1; SMN2
SCHEMBL2316025 0.82 PLA2G7 (0.34) PLA2G7NPC1RAB9ACYP1A2SMN1; SMN2
SCHEMBL8129041 0.82 PTGS1 (0.38) NPC1RAB9ACYP1A2SMN1; SMN2PTGS1
SCHEMBL11720223 0.80 NOTUM (0.35) TSHRNOTUM
SCHEMBL8131053 0.77 PTGS1 (0.37) CYP1A2PTGS1PTGS2HSD11B1ALDH1A1
SCHEMBL5281695 0.76 PLA2G7 (0.47) PLA2G7NPC1RAB9ACYP1A2SMN1; SMN2
SCHEMBL6011010 0.74 MEN1 (0.39) RAB9ACYP1A2SMN1; SMN2HPGDMEN1
SCHEMBL227893 0.72 TRPA1 (0.34) CYP1A2
SCHEMBL18039125 0.70 ALDH1A1 (0.40) NPC1RAB9ASMN1; SMN2HSD17B10PBRM1
SCHEMBL21620288 0.70 CYP1A2 (0.46) PLA2G7NPC1RAB9ACYP1A2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190490-A1 OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS SANOFI-AVENTIS (FR) 2011-08-04 US disclosed
EP-1028945-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS Amgen Inc. (US) 2000-08-23 EP disclosed
WO-1999024404-A1 SUBSTITUTED PYRIDINE COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AMGEN INC. (US) 1999-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190490-A1 OXAZOLOPYRIMIDINES AS EDG-1 RECEPTOR AGONISTS EDNRA, OXGR1, EDF1 PLA2G7 415/4885NPC1 4048/4885RAB9A 4635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.